312 related articles for article (PubMed ID: 8538196)
1. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?
Alberts DS; Hixson L; Ahnen D; Bogert C; Einspahr J; Paranka N; Brendel K; Gross PH; Pamukcu R; Burt RW
J Cell Biochem Suppl; 1995; 22():18-23. PubMed ID: 8538196
[TBL] [Abstract][Full Text] [Related]
2. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels.
Piazza GA; Alberts DS; Hixson LJ; Paranka NS; Li H; Finn T; Bogert C; Guillen JM; Brendel K; Gross PH; Sperl G; Ritchie J; Burt RW; Ellsworth L; Ahnen DJ; Pamukcu R
Cancer Res; 1997 Jul; 57(14):2909-15. PubMed ID: 9230200
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
[TBL] [Abstract][Full Text] [Related]
5. Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane.
Kishimoto Y; Takata N; Jinnai T; Morisawa T; Shiota G; Kawasaki H; Hasegawa J
Gut; 2000 Dec; 47(6):812-9. PubMed ID: 11076880
[TBL] [Abstract][Full Text] [Related]
6. Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention.
Earnest DL; Hixson LJ; Alberts DS
J Cell Biochem Suppl; 1992; 16I():156-66. PubMed ID: 1305681
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
8. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
9. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention.
DuBois RN; Giardiello FM; Smalley WE
Gastroenterol Clin North Am; 1996 Dec; 25(4):773-91. PubMed ID: 8960892
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer.
Levy GN
FASEB J; 1997 Mar; 11(4):234-47. PubMed ID: 9068612
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer.
Patrignani P
Toxicol Lett; 2000 Mar; 112-113():493-8. PubMed ID: 10720771
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.
Rao CV; Rivenson A; Simi B; Zang E; Kelloff G; Steele V; Reddy BS
Cancer Res; 1995 Apr; 55(7):1464-72. PubMed ID: 7882354
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac.
Agarwal B; Rao CV; Bhendwal S; Ramey WR; Shirin H; Reddy BS; Holt PR
Gastroenterology; 1999 Oct; 117(4):838-47. PubMed ID: 10500066
[TBL] [Abstract][Full Text] [Related]
16. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction.
Rigas B; Shiff SJ
Med Hypotheses; 2000 Feb; 54(2):210-5. PubMed ID: 10790755
[TBL] [Abstract][Full Text] [Related]
17. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
Pereira MA
Adv Exp Med Biol; 1999; 470():55-63. PubMed ID: 10709674
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase as a target for colorectal cancer chemoprevention.
Moreira L; Castells A
Curr Drug Targets; 2011 Dec; 12(13):1888-94. PubMed ID: 21158711
[TBL] [Abstract][Full Text] [Related]
19. Prevention of gastrointestinal cancer--the potential role of NSAIDs in colorectal cancer.
Luk GD
Schweiz Med Wochenschr; 1996 May; 126(19):801-12. PubMed ID: 8693304
[TBL] [Abstract][Full Text] [Related]
20. Colon cancer prevention by NSAIDs: what is the mechanism of action?
Ahnen DJ
Eur J Surg Suppl; 1998; (582):111-4. PubMed ID: 10029375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
